Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

Recruiting
18 years or above
All
Fase 1/2
12 participants needed
1 Location

Brief description of study

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: NSCLC Stage IV, ALK Fusion Protein Expression
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)
  2. Documented ALK rearrangement as detected by: (1) fluorescence in situ hybridization (FISH), (2) immuno-histochemistry (IHC), (3) tissue next-generation sequencing (NGS), or (4) circulating tumor DNA (ctDNA) NGS
  3. Ongoing treatment with crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib with at least stable disease ≥ 4 months
  4. No known presence of the specific ALK acquired resistance alterations targeted by the study vaccine
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  6. Males or females at least 18 years old

Exclusion Criteria:

  1. Known additional malignancy that is progressing or has required active treatment within the past 3 years. Adequately resected non-melanoma skin cancer, curatively treated in-situ disease, and other solid tumors treated with potentially curative therapy are allowed.
  2. Cytotoxic chemotherapy within 14 days of first dose of study vaccine or concurrent with study vaccine
  3. Anti-neoplastic immunotherapy within 28 days of first dose of study vaccine or concurrent with study vaccine

  4. Systemic immune suppression:

    1. Use of chronic oral or systemic steroid medication (topical or inhalational steroids are permitted)
    2. Other clinically relevant systemic immune suppression
  5. Symptomatic central nervous system (CNS) metastasis. Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted
  6. Current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression are allowed

Updated on 20 May 2024. Study ID: NCT05950139

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language